LIST OF FIGURES

Figure no. Title Page number

Figure 4.1 Dose dependent effect of CP on cell viability in A549 26
cells by MTT assay The results represented are the
mean±S.E.M of three independent experiments
performed in triplicate (***p < 0.0001) represent
significant difference compared with control) analyzed
by two-way ANOVA.
Figure 4.1 Dose dependent effect of TQ on cell viability in A549 27
cells by MTT assay The results represented are the
mean±S.E.M of three independent experiments
performed in triplicate (*p< 0.05 and ***p < 0.0001)
represent significant difference compared with control)
analyzed by two-way ANOVA.
Figure 4.2 Dose dependent effect of THY on cell viability in A549 28
cells by MTT assay The results represented are the
mean±S.E.M of three independent experiments
performed in triplicate (**p<0.05 and ***p < 0.0001)
represent significant difference compared with control)
analyzed by two-way ANOVA.
Figure 4.4 Effect of cytotoxicity of combined doses of THY+TQ in 29
A549 cells. The results represented are the mean±S.E.M
of three independent experiments performed in triplicate
(***p < 0.001 represent significant difference compared
with control).

Figure 4.5 Effect of toxicity of single (CP, THY and TQ) and 30
combined doses of THY+TQ in A549 cells. The results
represented are the mean±S.E.M of three independent
experiments performed in triplicate (***p < 0.001
represent significant difference compared with control).

x
Figure 4.6 4.6 Phase-contrast photomicrograph of A549 cells 31
treated with IC50 concentration of CP, THY, TQ and
THY+TQ for 24 h. Images presented are the
representatives of three independent experiments.
Figure 4.7 Synergistic effect of THY+TQ has shown an inhibition 34
of the migration of the A549 cells.

Figure 4.8 Quantitative real-time RT-PCR for assessing the 34-35

expression of VEGFR-2 in A549 cells exposed to
different treatments. Results are presented as mean ±
SEM (n = 3); ***P<0.001, compared with control,
analyzed by one-way ANOVA (Dunnet’s multiple
comparison test).
Figure 4.9 Binding orientations in the docked complexes of the 35
selected compounds, thymol (THY, a), thymoquinone
(TQ, b), and carboplatin (CP, c) with VEGFR-2. The
compounds are represented in green. Images were
generated using Discovery Studio visualizer.

xi